Ronald P. Dudek Email & Phone Number

Washington, DC, US

Wilmington, Delaware, United States

ABOUT CELLERGY PHARMACellergy Pharma is a privately-held biotechnology company that is developing novel CAR T cell products for treating severe atopic allergic diseases. The company is at the forefront of moving CAR T cells beyond the treatment of cancer, to the treatment of diseases caused by the immune system. Cellergy’s Lead product, CP-010, is in.

Rockville, Maryland, United States

CAR T Cells provides consulting services in the areas of chimeric antigen receptor engineered T cells (CAR T cells), T-cell receptor engineered T cells (TCR T cells), and in immunotherapy, in general. Adapter CAR (switchable CAR) is an area of unique expertise.

Gaithersburg, MD

I joined Miltenyi upon the acquisition of my third CAR T cell startup, Living Pharma. I worked with an amazingly talented and hard-working group to develop the Adapter CAR™ platform. Applications include hematological and solid organ cancers. Marketing chops: I convinced the company to trademark "Adapter CAR", and worked with the legal team to do it. I.

Baltimore, Maryland Area

Living Pharma was the first Adapter CAR (switchable CAR) T cell company in the world, and the third CAR T cell company that I have founded.An Adapter CAR, or switchable CAR, is a chimeric antigen receptor that recognizes a tag in a targeting molecule. Tagged fragment antibodies are common, but the technology can be used with any class of targeting.

Greater Seattle Area

Juno Therapeutics is commercializing chimeric antigen receptor engineered T cells (CAR T cells) for the treatment of cancer. I joined Juno from my second CAR T cell startup, Restoration Oncology, and brought into the company what became the lead CAR T cell product, JCAR015.Juno Therapeutics was founded upon acquiring ZetaRx Biosciences, Inc, a Mike Jensen.

Greater Seattle Area

Restoration Oncology, Inc. (ROI) is the second CAR T cell company that I have started. ROI was founded by two of the former ImmunoStem founders (See ImmunoStem below). We licensed three CAR T cell patents from Memorial Sloan Kettering Cancer Center including the in-the-news CD19 CAR patent, and a very interesting CAR T cells from stem cells patent, first.

Solutions for the manufacture of cellular therapies. I was the US cell therapy SME for SANYO Biomedical which was acquired by PHCNA. SANYO had designed and built Dr. Shinya Yamanaka's GMP cell manufacturing suites in Osaka, Japan. I helped develop GMP manufacturing labs at several academic and industrial sites. The position allowed for an excellent.

Greater Seattle Area

Radiant Biosciences offered label-free technology consulting services. Clients include Silicon Kinetics, Inc., Plexera, LLC, and others. I set up evaluations of the Silicon Kinetics SKiPro System at several antibody discovery companies, and helped develop applications of their unique label-free technology. I also consulted at the re-born Plexera.

Bothell, WA

Co-founder of this spinout from public photonics company Lumera Corporation (LMRA). Plexera Bioscience developed high-throughput, label-free drug discovery technology using high-density surface plasmon resonance (SPR) microarrays. I designed the business plan for the company, focusing the developing technology in the antibody discovery market. Applications.

Greater Seattle Area

ImmunoStem made what was, in 2015, a startling proposal - allogeneic T cells including CAR T cells made from stem cells. Lead product ISI-001 was a polyclonal anti-EBV T cell product made from healthy donors. CD19 and CD20 CAR T cells were in the pipeline. ImmunoStem's RegenImmune platform manufactured CAR T cells from stem cells using the OP9-DL1 system.

Greater Seattle Area

Xcyte Therapies developed T cell immunotherapies for oncology indications. Xcyte’s Xcellerated T Cells™ lead product did not perform well in clinical studies, and the company ceased operations. Compared to today’s technology, Xcyte’s was equivalent to expanding all of the hay in a haystack to look for the needle, but the company did develop a key tool for.

Ann Arbor, MI

Aastrom (Ann Arbor Stromal Cell) Biosciences’ original mission was to develop bone marrow expansion technology, the rationale being that a single bone marrow aspirate could be expanded to yield a complete cellular product suitable for transplantation. Unfortunately, the company was never able to expand hematopoietic stem cells, and the field began moving.

Auburn, CA

Miltenyi Biotec markets the CliniMACS Cell Selection System used in stem cell therapy applications. I was the business unit manager for clinical products, North America. The leading clinical application of the CliniMACS was selection of HSC's from haploidentical donors for allogenic HSC transplantation. Emerging applications included cellular immunotherapy.

Hercules, CA

Bioinstrumentation product management. A leading program was clinical microbiology flow cytometry including rapid antimicrobial susceptibility testing and rapid UTI screening.

La Jolla, CA

I developed antibody drug conjugates (ADC's), antibody toxin conjugates and radioimmunoconjugates. I managed an immune tolerance research project.

La Jolla, CA

I was engaged in studying the T-cell receptor repertoire, prior to the elucidation of the structure of the T cell receptor. I was fortunate to have worked in the visionary Linda Sherman/Norman Kleinman lab during a remarkable time in the field of immunology.

Mba, Finance, Marketing

My Master's thesis concerned an LBO analysis of US pharmaceutical companies.

Bs, Summa Cum Laude, Biological Science

Activities and Societies: Phi Beta Kappa